Energy Technologies has reported a deeper FY2026 loss, collapsing revenue and a $22.65 million equity deficiency, with its auditor flagging material uncertainty over the group’s ability to continue as a going concern. A five-year laser optics licence offers a potential new revenue path, but it remains conditional on development and future commercial sales.
- FY2026 loss attributable to shareholders widened to $12.477 million
- Revenue fell 51% to $3.946 million
- Auditor highlighted material uncertainty over going concern
- Group carried $24.873 million of borrowings at year end
- Cogenic licence offers a potential 5% future royalty
Going Concern Warning Overshadows Laser Optics Pivot
Energy Technologies Limited (ASX:EGY) is trying to fund a technology pivot while its existing finances remain under severe strain. The company reported a $12.477 million loss attributable to shareholders for FY2026, revenue of just $3.946 million and a net equity deficiency of $22.651 million. Crowe Audit Australia issued an unmodified audit opinion, but separately highlighted a material uncertainty that may cast significant doubt on the group’s ability to continue as a going concern.
The warning is grounded in hard numbers. Operating cash outflow was $4.443 million during the year, while the group’s net current asset deficit widened to $30.587 million. Cash at 30 June 2026 was $274,850 against total borrowings of $24.873 million, much of it carrying high interest rates. The company says it is relying on further capital raisings, lender support, debt extensions and improved operating performance to support its forecasts through September 2027.
Revenue Collapse Leaves Bambach Carrying the Burden
Revenue fell from $8.069 million to $3.946 million, while the group recorded a gross loss of $2.279 million. Finance costs rose to $4.318 million from $2.918 million, reflecting the weight of the funding structure. Bambach Wires & Cables reported an $8.103 million loss, although that was a modest improvement on the $8.490 million loss recorded in FY2025.
Management attributed the revenue decline to a strategic shift at Bambach as it repositioned the cable business towards higher-margin manufactured products, purchased product and renewable energy opportunities. The company says its order book has recently moved towards previous levels, with revenue expected to benefit in the third quarter of FY2027, subject to sufficient working capital and raw material availability. That qualification is doing considerable work: the report identifies cash constraints as a factor preventing the Rosedale factory from operating at full capacity.
Cogenic Licence Creates Potential but Not Current Revenue
The more ambitious part of the strategy sits with Cogenic, which acquired Maradin’s Laser Optical Engineering intellectual property portfolio in March. The portfolio includes 14 global patents covering Laser Beam Scanning technology for ultra-near-eye and direct-retina display applications. Cogenic subsequently entered a five-year Master Licence Agreement with Tennessee-based Amalgamated Vision to develop a lightweight, low-power optical platform for defence, first responder and aerospace applications, including work associated with AFWERX and NASA.
Under the arrangement, Cogenic would receive a 5% royalty on gross sales if the development produces a finished product that achieves commercial sales. The filing is explicit that the agreement generates no immediate revenue and that development resources will be used before contracted revenue exists. The intellectual property was recorded at $965,791 at year end, with further staged payments of about $779,000 still disclosed as payable in US dollar equivalents.
Capital and Debt Maturities Remain the Immediate Test
Energy Technologies raised $2.395 million through share issues during FY2026 and raised $6.835 million in borrowings, while repaying $3.036 million of debt. Post year end, it received a further $1.18 million in unsecured short-term loans at 18% interest and secured an extension of $2.02 million of convertible notes to September 2027. The balance sheet nevertheless contained $10.356 million of convertible notes classified as current at 30 June, alongside other short-term loans bearing rates of up to 20%.
The company also issued 46 million options on 28 August at an exercise price of 2.4 cents, including 26 million to key management personnel. Its share count had already reached 624.7 million at year end after placements priced at 2 cents a share. The report’s central tension is therefore difficult to miss: Cogenic may eventually provide a capital-light licensing engine, while Bambach may recover if working capital returns, but both propositions must progress before the financing burden becomes less urgent.
Bottom Line?
The next decisive evidence will be cash generation, debt management and a commercial milestone from Cogenic, not another statement of strategic intent.
Questions in the middle?
- Can Energy Technologies secure enough capital and lender support to bridge its current funding gap?
- Will Bambach’s recovering order book translate into positive margins and cash conversion in FY2027?
- When, if ever, will the Amalgamated Vision project produce a commercial product and royalty revenue?